• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why GameStop Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

    3/22/23 8:07:20 AM ET
    $BWV
    $CISO
    $CXAI
    $DBD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Professional Services
    Consumer Discretionary
    Get the next $BWV alert in real time by email

    Gainers

    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) shares rose 81.2% to $0.8032 in pre-market trading. Richard Branson's Virgin Orbit is nearing a deal for a $200 million investment from Texas-based Venture Capital investor Matthew Brown via a private share placement, according to a term sheet.
    • GameStop Corp. (NYSE:GME) climbed 43.7% to $25.37 in pre-market trading after the company reported better-than-expected Q4 results.
    • Diebold Nixdorf, Incorporated (NYSE:DBD) gained 23.1% to $0.9746 in pre-market trading. Diebold Nixdorf confirms closing on $55 million of additional liquidity.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) gained 22.1% to $0.88 in pre-market trading after dropping 13% on Tuesday.
    • Pyxis Oncology, Inc. (NASDAQ:PYXS) rose 21.4% to $2.67 in pre-market after dropping around 7% on Tuesday.
    • Blue Water Vaccines, Inc. (NASDAQ:BWV) gained 16.2% to $1.22 in pre-market trading. Blue Water Vaccines recently posted upbeat FY22 earnings.
    • Telesis Bio, Inc. (NASDAQ:TBIO) shares rose 12.2% to $2.48 in pre-market trading following better-than-expected Q4 results.
    • Hempacco Co., Inc. (NASDAQ:HPCO) rose 11.3% to $0.6901 in pre-market trading after declining 3% on Tuesday.
    • Kalera Public Limited Company (NASDAQ:KAL) shares rose 9.5% to $3.70 in pre-market trading.
    • Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) shares rose 9.4% to $9.68 in pre-market trading after dropping 24% on Tuesday.

    Losers

    • Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) fell 15.8% to $0.3250 in pre-market trading. Cerberus Cyber Sentinel shares climbed around 68% on Tuesday after the company announced certain preliminary estimated financial information of Q4 and FY2022.
    • WaveDancer, Inc. (NASDAQ:WAVD) fell 12.4% to $0.5567 in pre-market trading. WaveDancer said it has sold its blockchain-enabled supply chain management software subsidiary, Gray Matters, Inc. to Gray Matters Data, whose lead investor is venture capital firm StealthPoint.
    • CXApp Inc. (NASDAQ:CXAI) shares dropped 10.8% to $1.63 in pre-market trading after dropping 6% on Tuesday.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) fell 10.5% to $0.34 in pre-market after jumping around 90% on Tuesday. Impac Mortgage Holdings recently reported Q4 results.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) fell 10.1% to $0.3012 in pre-market trading after surging around 60% on Tuesday. Pear Therapeutics recently said it is exploring strategic alternatives and said it may seek a reorganization if it is unable to complete a transaction.
    • NuCana plc (NASDAQ:NCNA) fell 9.6% to $1.51 in pre-market trading after jumping over 32% on Tuesday.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) fell 8.9% to $0.1267 in pre-market trading after gaining 37% on Tuesday.
    • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares fell 8.8% to $1.04 in pre-market trading. Qualigen Therapeutics shares jumped over 16% on Tuesday after the company announced the USPTO granted it patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate.
    • Qutoutiao Inc. (NASDAQ:QTT) shares fell 7.9% to $0.2722 in pre-market trading. Qutoutiao shares dropped over 57% on Tuesday after the company received a letter from Nasdaq indicating it has determined to delist the company's stock. The company said it elected not to appeal the determination..
    • Gelesis Holdings, Inc. (NYSE:GLS) fell 7.4% to $0.1466 in pre-market trading after declining around 25% on Tuesday.

    Now Read This: Top 3 Utilities Stocks Which Could Rescue Your Portfolio This Month

    Get the next $BWV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWV
    $CISO
    $CXAI
    $DBD

    CompanyDatePrice TargetRatingAnalyst
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    Pyxis Oncology Inc.
    $PYXS
    9/4/2025$5.00Buy
    Guggenheim
    Pyxis Oncology Inc.
    $PYXS
    11/21/2024Outperform → Mkt Perform
    William Blair
    Pyxis Oncology Inc.
    $PYXS
    11/8/2024$13.00Overweight
    Stephens
    NuCana plc
    $NCNA
    8/30/2024Outperform → Mkt Perform
    William Blair
    Pyxis Oncology Inc.
    $PYXS
    8/8/2024$10.00Buy
    Stifel
    Pyxis Oncology Inc.
    $PYXS
    5/7/2024$10.00Buy
    Jefferies
    Diebold Nixdorf Incorporated
    $DBD
    5/3/2024$40.00 → $50.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $BWV
    $CISO
    $CXAI
    $DBD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GameStop Announces Release Date for Fourth Quarter and Fiscal Year 2025 Results

    GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today announced that it will report its fourth quarter and fiscal year 2025 results after the market closes on Tuesday, March 24, 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260316046838/en/ GameStop Corp. Investor Relations (817) 424-2001 [email protected]

    3/16/26 4:20:00 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    JN Bank Expands Self-Service Banking Across Jamaica with Diebold Nixdorf's Cash Recyclers

    Empowering members with more convenient, secure and reliable banking through advanced technology and local expertiseNORTH CANTON, Ohio, March 10, 2026 /PRNewswire/ -- Diebold Nixdorf (NYSE:DBD), a world leader in transforming the way people bank and shop, today announced the successful expansion of JN Bank's self-service network across Jamaica with the rollout of DN Series® 200V cash recyclers. This marks a significant leap in self-service banking for the Caribbean, delivering advanced cash recycling and a more secure, personalized experience to nearly 1 million JN Bank members. Installation and services for this implementation were provided by MC Systems, Diebold Nixdorf's licensed partner

    3/10/26 8:07:00 AM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    $BWV
    $CISO
    $CXAI
    $DBD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $BWV
    $CISO
    $CXAI
    $DBD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lee Yan Kit Raymond

    3 - Lixiang Education Holding Co. Ltd. (0001814067) (Issuer)

    3/19/26 6:48:09 AM ET
    $LXEH
    Other Consumer Services
    Real Estate

    SEC Form 3 filed by new insider Heng Teck Yong

    3 - Lixiang Education Holding Co. Ltd. (0001814067) (Issuer)

    3/19/26 6:35:49 AM ET
    $LXEH
    Other Consumer Services
    Real Estate

    SEC Form 3 filed by new insider Kay Andrew Martin

    3 - NuCana plc (0001709626) (Issuer)

    3/18/26 5:36:55 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $CISO
    $CXAI
    $DBD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Pyxis Oncology with a new price target

    Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00

    11/3/25 9:08:29 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Pyxis Oncology with a new price target

    Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00

    9/4/25 9:07:21 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology downgraded by William Blair

    William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

    11/21/24 7:55:42 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $CISO
    $CXAI
    $DBD
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by NuCana plc

    SCHEDULE 13D - NuCana plc (0001709626) (Subject)

    3/18/26 6:39:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CXApp Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - CXApp Inc. (0001820875) (Filer)

    3/12/26 9:00:41 AM ET
    $CXAI
    EDP Services
    Technology

    SEC Form 424B3 filed by CXApp Inc.

    424B3 - CXApp Inc. (0001820875) (Filer)

    3/12/26 9:00:41 AM ET
    $CXAI
    EDP Services
    Technology

    $BWV
    $CISO
    $CXAI
    $DBD
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $CISO
    $CXAI
    $DBD
    Financials

    Live finance-specific insights

    View All

    Diebold Nixdorf Reports 2025 Fourth Quarter and Full-Year Financial Results; Company Grew Revenue and Adjusted EBITDA, and More Than Doubled Free Cash Flow in FY 2025

    Company establishes new 2026 financial outlook, above previous targets provided at 2025 Investor DayOrder entry grew 17%, with revenue growth of ~2% YoY Free cash flow more than doubled YoY to a company recordAdjusted EPS more than doubled YoY Executing on new $200 million share repurchase program following completion of initial $100 million program in Q4; repurchased approximately $128 million of shares, or ~6% of the company's total shares outstanding in FY 2025Materials and investor call information available at http://www.dieboldnixdorf.com/earningsNORTH CANTON, Ohio, Feb. 12, 2026 /PRNewswire/ -- Diebold Nixdorf (NYSE:DBD), a world leader in transforming the way people bank and shop, to

    2/12/26 7:00:00 AM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    Diebold Nixdorf to Conduct 2025 Fourth Quarter, Full-Year Investor Call on Feb. 12

    NORTH CANTON, Ohio, Jan. 22, 2026 /PRNewswire/ -- Diebold Nixdorf (NYSE:DBD), a world leader in transforming the way people bank and shop, will release fourth quarter and full-year 2025 financial results on Thursday, Feb. 12, before trading begins on the New York Stock Exchange. Octavio Marquez, president and chief executive officer, and Tom Timko, executive vice president and chief financial officer, will discuss the results during a conference call and webcast that day beginning at 8:30 a.m. ET. Earnings Call Details: Date: Thursday, Feb. 12Time: 8:30am ETWebcast: Diebold Ni

    1/22/26 8:15:00 AM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp

    12/18/25 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $CISO
    $CXAI
    $DBD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CXApp Inc.

    SC 13G/A - CXApp Inc. (0001820875) (Subject)

    11/13/24 4:40:58 PM ET
    $CXAI
    EDP Services
    Technology

    SEC Form SC 13G filed by CXApp Inc.

    SC 13G - CXApp Inc. (0001820875) (Subject)

    11/12/24 3:11:40 PM ET
    $CXAI
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Diebold Nixdorf Incorporated

    SC 13G/A - DIEBOLD NIXDORF, Inc (0000028823) (Subject)

    11/12/24 2:36:04 PM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous